Takeda Announces EMA Acceptance of MAA for Adcetris

Takeda Pharmaceutical Company Limited together with its wholly-owned subsidiary Millennium: The Takeda Oncology Company today announced that the European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for Adcetris (brentuximab vedotin) for the treatment of relapsed or refractory Hodgkin lymphoma (HL) and relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).
Gamut News